Clinical Diagnosis

Bonnie An Henderson, MD, founder and program director of EnVision Summit, previews what attendees can expect at this year’s meeting - from its diverse faculty to an inclusive Youth Program, while also giving back to the community. The conference will take place February 17 to 20 at the El Conquistador Resort in Fajardo, Puerto Rico.

The approval of aflibercept for preterm infants with retinopathy of prematurity (ROP) expands the treatment armamentarium for these patients, comments Prof Anat Loewenstein.

Robert L. Stamper, MD, discusses some of the devices in development for measuring patients' intraocular pressure outside of doctors' office hours in his presentation at Glaucoma Research Foundation's annual Glaucoma Symposium.

Shan C. Lin, MD, provides an overview of the various intraocular lens technologies that are available, as well as considerations for contrast sensitivity and vision loss in patients at Glaucoma Research Foundation's annual Glaucoma Symposium.

Ying Han, MD, PhD, provides some key takeaways from her Glaucoma 360 2023 presentation, "Tube shunt update."

Kristen H. Ingenito, MBA, vice president and director of ophthalmics at Market Scope, discusses the volume of ophthalmologists offering interventional glaucoma treatment as well as emerging therapies in her presentation at the Glaucoma 360 New Horizons Forum.

Let us know how familiar are you on the approval process for biosimilar drugs compared with new drug applications to the FDA. The poll will be open until February 28, 2023.

Timely access to effective diagnosis and cross-linking is key to positive outcomes

Continued education and financial incentives will become essential if biosimilars are to become a mainstay in ophthalmological markets, according to a recent report.

On this week's episode of the NeuroOp Guru video blog, Andy Lee, MD, and Elizabeth Fortin, MD, discuss Thymectomy in Ocular Myasthenia Gravis, Yes or No?

Automated AI tool offers offline capability and hope for patients.

Previous research conducted primarily by scientists at the University of São Paulo, Brazil, showed brilacidin can potentiate several marketed antifungals, including caspofungin, voriconazole and posaconazole.

Survey of academic chairs and residency directors recognizes centers of excellence in Best Clinical Care, Best Residency, Best Research, and Best Overall Programs.

Spanish investigators found that local resection may offer better visual results and eye sparing without compromising local tumor control and survival.

Results from our recent poll indicate a mixed bag of responses from ophthalmologists.

Jefferson Doyle, MBBCh, MD, PhD, MHS, of the Wilmer Eye Institute at Johns Hopkins University School of Medicine, addresses myopic concerns, such as public health measures including time outdoors, as well as pharmacological approaches including the current atropine data that has been completed and ongoing studies.

Ophthalmology Times®' EyeCon co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and glaucoma specialist Oluwatosin U. Smith MD, from Glaucoma Associates of Texas, discuss some of the highlights of EyeCon 2022.

Stephen Pflugfelder, MD, professor and director of the Ocular Surface Center at Baylor College of Medicine in Houston, Texas, presents a challenging diagnostic dilemma.

Rishi Singh, MD, of Cleveland Clinic Florida, touches upon the various advancements that are making a difference for clinicians and patients and reducing their progression in this disease state.

Julius Oatts, MD, covered a range of current considerations for retinopathy of prematurity (ROP), including the updated International Classification for ROP, clinical research, and some of the socioeconomic factors that affect ROP. Oatts is assistant professor and associate residency program director with the Department of Ophthalmology at the University of California, San Francisco.

The drug is expected to be available to eye care clinicians in the US during the second half of 2023.

According to researcher, the treatment offers improved retinal sensitivity, visual function, and mobility.

Ophthalmologist discusses the impact of getting older on patients diagnosed with the disease.

AZR-MD-001 is currently being studied to evaluate the safety, efficacy, and tolerability of the study drug in patients with MGD.

CXL has been proven effective to treat patients with corneal ectasias.